PER-034-04已完成未知
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE CLINICAL EFFECTS OF MONTELUKAST INTRAVENOUS WITH PLACEBO IN PATIENTS WITH ACUTE ASTHMA
MERCK & CO.INC.,0 个研究点目标入组 0 人开始时间: 2004年6月15日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •The patient is a male or female at least 15 years of age.
- •Not pregnant.
- •Asthma history of at least 1 year.
- •During Period I, the patient has a forced expiratory volume in 1 second (FEV1) <50% of the predicted value in all measurements.
排除标准
- •The patient has some known or suspected cause, acute or chronic. for your pulmonary symptoms other than asthma.
- •Patients with fever.
- •The patient has received any anti-asthmatic therapy other than oxygen, pagonists, anticholinergics, or corticosteroids.
- •The patient has some comorbidity alteration different to asthma diagnosed by history, physical examination, or laboratory results.
研究者
相似试验
已完成
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE CLINICAL EFFECTS OF MONTELUKAST INTRAVENOUS WITH PLACEBO IN PEDIATRIC PATIENTS (BETWEEN 6 AND 14 YEARS OLD) WHO SUFFER FROM ACUTE ASTHMA-J459 Asthma, unspecifiedAsthma, unspecifiedJ459PER-028-05MERCK & CO.INC.,
已完成
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE CLINICAL EFFECT OF MONTELUKAST INTRAVENOUS WITH PLACEBO IN PATIENTS WITH ACUTE ASTHMA-J451 Nonallergic asthmaNonallergic asthmaJ451PER-050-01MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY AND SAFETYOF CADAZOLID VERSUS VANCOMYCIN IN SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATEDDIARRHEA (CDAD)-A047 Enterocolitis due to Clostridium difficileEnterocolitis due to Clostridium difficileA047PER-087-13Actelion Pharmaceuticals Ltd,1
已完成
不适用
Montelukast Asthmatic Smoker Study-J459 Asthma, unspecifiedAsthma, unspecifiedJ459PER-008-06MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF THE EFFICACY, TOLERABILITY AND SAFETY OF VALDECOXIB (BEXTRA®)10 MG OD VS. DICLOFENAC SODIUM 50 MG TDS FOR 6 WEEKS IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE. - N/AOsteoarthritis of the kneeClassification code 10031161EUCTR2004-001713-34-GBPfizer Limited516